JB Chemicals & Pharmaceuticals Limited — Others, 11-07-2025: Shareholders meeting

J.B. Chemicals & Pharmaceuticals has announced a board meeting on August 6, 2025, to approve the financial results for the quarter and half-year. The company will hold its 49th Annual General Meeting through video conferencing to adopt audited financial statements, confirm an interim dividend of ₹8.50 per share, and declare a final dividend of ₹7.00 per share. Key agenda includes re-appointment of Deloitte Haskins & Sells LLP as statutory auditors for five years, appointment of three new independent directors, and re-appointment of Mr. Nikhil Chopra as CEO and Whole-Time Director with revised remuneration of ₹10 Cr per annum for a five-year term starting October 2025. The registered office will be shifted from Mumbai to Ahmedabad, subject to regulatory approvals, to facilitate the proposed amalgamation with Torrent Pharmaceuticals. Secretarial auditors M/s N.L. Bhatia & Associates and cost auditors Kishore Bhatia & Associates have been appointed. Shareholders will also vote on waiving lock-in restrictions on shares held by the CEO under the ESOP scheme in case of change in control.